Skip to main
HUMA
HUMA logo

Humacyte (HUMA) Stock Forecast & Price Target

Humacyte (HUMA) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Humacyte Inc's development of the Symvess product is anticipated to gain momentum by mid-2025, following approvals from hospital Value Analysis Committees (VACs), which could drive sales growth significantly. The adoption of Symvess is supported by insights indicating it offers cost savings for third-party payers by minimizing late complications, along with positive responses from surgeons regarding its clinical benefits, including higher patency rates and lower infection risks. Additionally, there is a particular emphasis on the product's potential in addressing peripheral artery disease (PAD), where its superior infection resistance presents a compelling alternative to traditional grafts, positioning Humacyte favorably for broader market acceptance.

Bears say

Humacyte Inc faces significant hurdles that negatively impact its financial outlook, including the risk of clinical trials failing to demonstrate efficacy, which could impede progress toward regulatory approval and commercialization. The company's prospects may also be hindered by challenges in establishing a competitive advantage for its products within targeted indications, alongside concerns regarding intellectual property protection and the potential need to raise funds under unfavorable market conditions. Additionally, the reliance on the advanced tissue engineered vessels (ATEV) amidst procedural limitations further compounds the uncertainty surrounding the company’s ability to secure market positioning and generate sustainable revenue.

Humacyte (HUMA) has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humacyte (HUMA) Forecast

Analysts have given Humacyte (HUMA) a Buy based on their latest research and market trends.

According to 10 analysts, Humacyte (HUMA) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humacyte (HUMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.